Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Viatris Inc.
  6. News
  7. Summary
    VTRS   US92556V1061

VIATRIS INC.

(VTRS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Viatris : Former Mylan executive pleads guilty to insider trading

09/17/2021 | 05:32pm EDT
Logo of Mylan Laboratories, a company primarily engaged in the commercialization of generic drugs is pictured in Merignac near Bordeaux

(Reuters) - A former information technology executive at Mylan pleaded guilty on Friday to insider trading for using tips from the drugmaker's chief information officer to trade in its stock, generating $4.27 million of illegal profit, authorities said.

Dayakar Mallu, 51, admitted to conspiring to commit securities fraud, and to an unrelated charge of helping prepare a false tax return, before U.S. District Judge W. Scott Hardy in Pittsburgh.

Mylan is now known as Viatris Inc after merging last November with Pfizer Inc's Upjohn off-patent drug business, which Pfizer spun off. The combined company's headquarters remain in Canonsburg, Pennsylvania, a Pittsburgh suburb.

Authorities said that between October 2017 and July 2019, Mallu traded Mylan stock based on material nonpublic information about the company's results, U.S. Food and Drug Administration drug approvals, and the Upjohn merger.

Mallu, now a resident of Orlando, Florida, was previously vice president of global operations information technology at Mylan, and had been a friend and colleague of the chief information officer, court records show.

The tax return charge related to a computer programming company based in Farmington Hills, Michigan, that Mallu owned, prosecutors said.

Mallu could face 57 to 71 months in prison under recommended federal guidelines at his Jan. 24, 2022, sentencing, according to a plea agreement with the U.S. Department of Justice.

He also agreed to forfeit $4.27 million and make restitution to the Internal Revenue Service, court records show. The U.S. Securities and Exchange Commission filed related civil charges.

Aitan Goelman, a lawyer for Mallu, declined to comment.

Ramkumar Rayapureddy, who was Mylan's CIO at the time of Mallu's trading, now holds the same job at Viatris, according to Viatris' website and his LinkedIn Page.

The SEC said Mallu shared some profits with the source of his inside information, who directed him to make cash payments in person, in India, to avoid detection.

Rayapureddy did not immediately respond to a request for comment.

In a statement, Viatris said: "The company is committed to the highest standards of integrity and compliance with the law. The company has been fully cooperating with the authorities. We are not in a position to comment further."

(Reporting by Jonathan Stempel in New York and Chris Prentice in Washington; editing by Jonathan Oatis)

By Jonathan Stempel and Chris Prentice


ę Reuters 2021
All news about VIATRIS INC.
10/21BIOCON : Biologics First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed wi..
AQ
10/20VIATRIS' : Semglee Insulin Injection to be Listed on Express Scripts' National Preferred F..
MT
10/20Cigna's pharmacy benefit unit to prefer cheaper insulin drug from Viatris
RE
10/13VIATRIS INC. : to Release Third Quarter 2021 Financial Results on Nov. 8, 2021
PR
10/12VIATRIS : Mapi Pharma to Present Series of Recent Advancements for Treating Multiple Scler..
AQ
10/11VIATRIS : Named Fifth on Fortune's Change the World List
PR
10/03PFIZER : to Transfer Upjohn Business to India's Mylan for $24 Million
MT
09/29INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims Against Via..
BU
09/17VIATRIS : Former Mylan executive pleads guilty to insider trading
RE
09/03JOHNSON & JOHNSON : Lifesaving TB Medicines Still Out of Reach for Children in High-Burden..
AQ
More news
Analyst Recommendations on VIATRIS INC.
More recommendations
Financials (USD)
Sales 2021 17 803 M - -
Net income 2021 -1 188 M - -
Net Debt 2021 22 703 M - -
P/E ratio 2021 -9,04x
Yield 2021 2,35%
Capitalization 16 858 M 16 858 M -
EV / Sales 2021 2,22x
EV / Sales 2022 2,07x
Nbr of Employees 40 000
Free-Float 99,7%
Chart VIATRIS INC.
Duration : Period :
Viatris Inc. Technical Analysis Chart | VTRS | US92556V1061 | MarketScreener
Technical analysis trends VIATRIS INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 13,94 $
Average target price 19,29 $
Spread / Average Target 38,3%
EPS Revisions
Managers and Directors
Michael Goettler Chief Executive Officer & Director
Rajiv Malik President & Director
Sanjeev Narula Chief Financial Officer
Robert J. Coury Executive Chairman
Ramkumar V. Rayapureddy Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
VIATRIS INC.-25.61%16 858
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.17.25%241 985
ELI LILLY AND COMPANY44.37%220 979